Please login to the form below

Not currently logged in
Email:
Password:

DVT

This page shows the latest DVT news and features for those working in and with pharma, biotech and healthcare.

FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis

FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis

BMS and Pfizer’s drug is also used to prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients who have undergone hip or knee replacement surgery, as a treatment ... of DVT and PE and for the reduction in the risk of recurrent DVT and

Latest news

More from news
Approximately 7 fully matching, plus 35 partially matching documents found.

Latest Intelligence

  • The rise of chronic disease in BRIC markets The rise of chronic disease in BRIC markets

    Cardiovascular diseases – such as heart attack, stroke, DVT and atrial fibrillation – also present a major problem in Russia, with 46 per cent of self-reported sufferers (39 per cent being diagnosed).

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    Certoparin sodium has been launched for the treatment of DVT and is in phase III trials for prevention of thrombosis in medically ill patients.

  • Go with the flow

    Find out if you are at risk of developing DVT in hospital by asking for a risk assessment.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
BOLDSCIENCE

We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics